NeoGenomics (NEO) Projected to Post Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) will likely be announcing its Q1 2025 earnings results before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $171.38 million for the quarter.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The company had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. On average, analysts expect NeoGenomics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Price Performance

NEO opened at $9.58 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The stock has a market capitalization of $1.23 billion, a P/E ratio of -15.45 and a beta of 1.41. The company’s 50 day simple moving average is $10.10 and its 200-day simple moving average is $13.57. NeoGenomics has a one year low of $8.05 and a one year high of $19.12.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. The Goldman Sachs Group dropped their price objective on NeoGenomics from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, April 17th. Needham & Company LLC lowered their price target on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Piper Sandler reduced their price objective on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Bank of America lowered their target price on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. Finally, Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, NeoGenomics has a consensus rating of “Moderate Buy” and an average price target of $19.30.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.